Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc–siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5′-exonuclease

Abstract In this report, we investigated the hexopyranose chemical modification Altriol Nucleic Acid (ANA) within small interfering RNA (siRNA) duplexes that were otherwise fully modified with the 2′-deoxy-2′-fluoro and 2′-O-methyl pentofuranose chemical modifications. The siRNAs were designed to silence the transthyretin (Ttr) gene and were conjugated to a trivalent N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes. Sense and antisense strands of the parent duplex were synthesized with single ANA residues at each position on the strand, and the resulting siRNAs were evaluated for their ability to inhibit Ttr mRNA expression in vitro. Although ANA residues were detrimental at the 5′ end of the antisense strand, the siRNAs with ANA at position 6 or 7 in the seed region had activity comparable to the parent. The siRNA with ANA at position 7 in the seed region was active in a mouse model. An Oligonucleotide with ANA at the 5′ end was more stable in the presence of 5′-exonuclease than an oligonucleotide of the same sequence and chemical composition without the ANA modification. Modeling studies provide insight into the origins of regiospecific changes in potency of siRNAs and the increased protection against 5′-exonuclease degradation afforded by the ANA modification.

[1]  M. Manoharan,et al.  The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs , 2019, Nature Nanotechnology.

[2]  Ryan L Setten,et al.  The current state and future directions of RNAi-based therapeutics , 2019, Nature Reviews Drug Discovery.

[3]  K. G. Rajeev,et al.  5'-Morpholino modification of the sense strand of an siRNA makes it a more effective passenger. , 2019, Chemical communications.

[4]  M. Manoharan,et al.  Re-Engineering RNA Molecules into Therapeutic Agents. , 2019, Accounts of chemical research.

[5]  K. G. Rajeev,et al.  Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates , 2019, Nucleic acids research.

[6]  K. G. Rajeev,et al.  CHAPTER 11. Liver-targeted RNAi Therapeutics: Principles and Applications , 2019, Drug Discovery.

[7]  H. Bonkovsky,et al.  Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria , 2019, The New England journal of medicine.

[8]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[9]  K. G. Rajeev,et al.  Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity , 2018, Nature Communications.

[10]  M. Moore,et al.  Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo , 2018, Nucleic acids research.

[11]  K. G. Rajeev,et al.  Facile Synthesis, Geometry, and 2'-Substituent-Dependent in Vivo Activity of 5'-(E)- and 5'-(Z)-Vinylphosphonate-Modified siRNA Conjugates. , 2018, Journal of medicinal chemistry.

[12]  D. Corey,et al.  Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs , 2017, Nucleic acids research.

[13]  K. G. Rajeev,et al.  4'-C-Methoxy-2'-deoxy-2'-fluoro Modified Ribonucleotides Improve Metabolic Stability and Elicit Efficient RNAi-Mediated Gene Silencing. , 2017, Journal of the American Chemical Society.

[14]  K. G. Rajeev,et al.  Chirality Dependent Potency Enhancement and Structural Impact of Glycol Nucleic Acid Modification on siRNA. , 2017, Journal of the American Chemical Society.

[15]  Ashish Ranjan Sharma,et al.  Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine , 2017, Molecular therapy. Nucleic acids.

[16]  M. Manoharan,et al.  siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2 , 2016, Nucleic acids research.

[17]  K. G. Rajeev,et al.  5′‐(E)‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates , 2016, Chembiochem : a European journal of chemical biology.

[18]  S. Chi,et al.  Rationally designed siRNAs without miRNA-like off-target repression , 2016, BMB reports.

[19]  S. Chi,et al.  Abasic pivot substitution harnesses target specificity of RNA interference , 2015, Nature Communications.

[20]  S. Milstein,et al.  Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification , 2015, Molecular therapy. Nucleic acids.

[21]  S. Milstein,et al.  Hepatocyte‐Specific Delivery of siRNAs Conjugated to Novel Non‐nucleosidic Trivalent N‐Acetylgalactosamine Elicits Robust Gene Silencing in Vivo , 2015, Chembiochem : a European journal of chemical biology.

[22]  Wenyu Li,et al.  Identification of metabolically stable 5′-phosphate analogs that support single-stranded siRNA activity , 2015, Nucleic acids research.

[23]  S. Milstein,et al.  siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. , 2015, ACS chemical biology.

[24]  Amy Chan,et al.  Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. , 2014, Journal of the American Chemical Society.

[25]  M. Manoharan,et al.  Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals. , 2013, ACS chemical biology.

[26]  Jing Liu,et al.  Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression , 2012, Cell.

[27]  Stanley T. Crooke,et al.  Single-Stranded siRNAs Activate RNAi in Animals , 2012, Cell.

[28]  G. Hannon,et al.  The Structure of Human Argonaute-2 in Complex with miR-20a , 2012, Cell.

[29]  I. MacRae,et al.  The Crystal Structure of Human Argonaute2 , 2012, Science.

[30]  P. Herdewijn,et al.  How does hydroxyl introduction influence the double helical structure: the stabilization of an altritol nucleic acid:ribonucleic acid duplex , 2012, Nucleic acids research.

[31]  J. Doudna,et al.  Coupled 5' nucleotide recognition and processivity in Xrn1-mediated mRNA decay. , 2011, Molecular cell.

[32]  K. G. Rajeev,et al.  Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs. , 2011, Angewandte Chemie.

[33]  B. Polisky,et al.  Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs , 2010, Nucleic acids research.

[34]  Eric B. Roesch,et al.  Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs , 2010, Artificial DNA, PNA & XNA.

[35]  F. Baas,et al.  In vivo efficacy and off-target effects of Locked Nucleic Acid (LNA) and Unlocked Nucleic Acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts , 2010, Artificial DNA, PNA & XNA.

[36]  J. Kjems,et al.  A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects , 2010, Nucleic acids research.

[37]  N. Sonenberg,et al.  Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing , 2010, Nucleic acids research.

[38]  T. Tuschl,et al.  Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes , 2009, Nature.

[39]  P. Herdewijn,et al.  Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf. , 2009, European journal of pharmacology.

[40]  J. Kjems,et al.  A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity , 2009, Nucleic acids research.

[41]  M. Behlke.  Chemical modification of siRNAs for in vivo use. , 2008, Oligonucleotides.

[42]  K. Ui-Tei,et al.  Thermodynamic stability and Watson–Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-target effect , 2008, Nucleic acids research.

[43]  P. Herdewijn,et al.  Inhibition of MDR1 expression with altritol-modified siRNAs , 2007, Nucleic acids research.

[44]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[45]  B. Polisky,et al.  Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication , 2005, Hepatology.

[46]  R. Griffey,et al.  Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. , 2005, Journal of medicinal chemistry.

[47]  M. Manoharan.  RNA interference and chemically modified small interfering RNAs. , 2004, Current opinion in chemical biology.

[48]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[49]  T. Rana,et al.  siRNA function in RNAi: a chemical modification analysis. , 2003, RNA.

[50]  David R Corey,et al.  RNA interference in mammalian cells by chemically-modified RNA. , 2003, Biochemistry.

[51]  Phillip A Sharp,et al.  siRNAs can function as miRNAs , 2003 .

[52]  A. Fire,et al.  Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[54]  P. Herdewijn,et al.  D-ALTRITOL NUCLEIC ACIDS (ANA) : HYBRIDISATION PROPERTIES, STABILITY, AND INITIAL STRUCTURAL ANALYSIS , 1999 .

[55]  P. Herdewijn,et al.  Synthesis of protected D-altritol nucleosides as building blocks for oligonucleotide synthesis , 1999 .

[56]  T. Steitz,et al.  Structural principles for the inhibition of the 3'-5' exonuclease activity of Escherichia coli DNA polymerase I by phosphorothioates. , 1998, Journal of molecular biology.

[57]  Wolfram Saenger,et al.  Principles of Nucleic Acid Structure , 1983 .